Teva Pharmaceutical Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $36.21 billion. The enterprise value is $51.10 billion.
Important Dates
The next confirmed earnings date is Wednesday, January 28, 2026, before market open.
| Earnings Date | Jan 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 2.33% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.15B |
| Shares Change (YoY) | +2.33% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 0.38% |
| Owned by Institutions (%) | 71.74% |
| Float | 1.14B |
Valuation Ratios
The trailing PE ratio is 51.14 and the forward PE ratio is 12.21. Teva Pharmaceutical's PEG ratio is 1.84.
| PE Ratio | 51.14 |
| Forward PE | 12.21 |
| PS Ratio | 2.15 |
| Forward PS | 2.09 |
| PB Ratio | 4.99 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 62.64 |
| P/OCF Ratio | 33.97 |
| PEG Ratio | 1.84 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 11.12, with an EV/FCF ratio of 88.40.
| EV / Earnings | 71.66 |
| EV / Sales | 3.05 |
| EV / EBITDA | 11.12 |
| EV / EBIT | 14.26 |
| EV / FCF | 88.40 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 2.36.
| Current Ratio | 1.11 |
| Quick Ratio | 0.52 |
| Debt / Equity | 2.36 |
| Debt / EBITDA | 3.61 |
| Debt / FCF | 29.57 |
| Interest Coverage | 3.75 |
Financial Efficiency
Return on equity (ROE) is 9.71% and return on invested capital (ROIC) is 8.95%.
| Return on Equity (ROE) | 9.71% |
| Return on Assets (ROA) | 5.49% |
| Return on Invested Capital (ROIC) | 8.95% |
| Return on Capital Employed (ROCE) | 12.63% |
| Revenue Per Employee | $455,498 |
| Profits Per Employee | $19,359 |
| Employee Count | 36,830 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.30 |
Taxes
In the past 12 months, Teva Pharmaceutical has paid $238.00 million in taxes.
| Income Tax | 238.00M |
| Effective Tax Rate | 26.44% |
Stock Price Statistics
The stock price has increased by +38.60% in the last 52 weeks. The beta is 0.67, so Teva Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | +38.60% |
| 50-Day Moving Average | 25.48 |
| 200-Day Moving Average | 19.15 |
| Relative Strength Index (RSI) | 79.88 |
| Average Volume (20 Days) | 9,281,733 |
Short Selling Information
| Short Interest | 44.94M |
| Short Previous Month | 46.44M |
| Short % of Shares Out | 3.94% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.18 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $16.78 billion and earned $713.00 million in profits. Earnings per share was $0.62.
| Revenue | 16.78B |
| Gross Profit | 8.40B |
| Operating Income | 3.58B |
| Pretax Income | 900.00M |
| Net Income | 713.00M |
| EBITDA | 4.59B |
| EBIT | 3.58B |
| Earnings Per Share (EPS) | $0.62 |
Full Income StatementBalance Sheet
The company has $2.20 billion in cash and $17.09 billion in debt, giving a net cash position of -$14.89 billion or -$12.98 per share.
| Cash & Cash Equivalents | 2.20B |
| Total Debt | 17.09B |
| Net Cash | -14.89B |
| Net Cash Per Share | -$12.98 |
| Equity (Book Value) | 7.25B |
| Book Value Per Share | 6.32 |
| Working Capital | 1.25B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.07 billion and capital expenditures -$488.00 million, giving a free cash flow of $578.00 million.
| Operating Cash Flow | 1.07B |
| Capital Expenditures | -488.00M |
| Free Cash Flow | 578.00M |
| FCF Per Share | $0.50 |
Full Cash Flow StatementMargins
Gross margin is 50.09%, with operating and profit margins of 21.35% and 4.25%.
| Gross Margin | 50.09% |
| Operating Margin | 21.35% |
| Pretax Margin | 5.36% |
| Profit Margin | 4.25% |
| EBITDA Margin | 27.38% |
| EBIT Margin | 21.35% |
| FCF Margin | 3.45% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.33% |
| Shareholder Yield | -2.33% |
| Earnings Yield | 1.97% |
| FCF Yield | 1.60% |
Dividend DetailsAnalyst Forecast
The average price target for Teva Pharmaceutical is $32.11, which is 1.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.11 |
| Price Target Difference | 1.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.62 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.62 |
| Piotroski F-Score | 7 |
